Going Back to a New Approach: FDA, Outside Experts, and Conflicts of Interest
This article was originally published in RPM Report
Executive Summary
FDA has gone far-maybe too far-in excluding outside experts from advisory committee panels who have potential conflicts of interest. The agency is considering easing back the restrictions. What will it mean for future external guidance to FDA?
You may also be interested in...
Conflict Over Conflicts: FDA Advisory Committee Rules May Be Ripe For Change
Recruitment of FDA advisory committee members has been a persistent challenge for the agency—especially since the conflict of interest rules were tightened five years ago. While FDA has improved the number of vacancies on its expert panels, it has yet to meet its goals—especially in the Center for Drugs. Congress is considering loosening the restrictions. Will that help, or simply fuel criticism of the process?
FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules
FDA is working on an initiative to fill many of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies
FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules
FDA is working on an initiative to fill many of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies